Skip to main content
OpenTrials

Clinical trial condition

Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

Explore clinical trials studying Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated). Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated) trial results

Completed

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

NCT03507452

Conditions
Adenoma, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated), Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, +15 more
Locations
  • National Cancer Institute - Maryland Bethesda, Maryland, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • HUS, Meilahden sairaala Helsinki, Finland
  • Nederlands Kanker Instituut Amsterdam, Netherlands
View Trial Details

Related conditions